EGFR and non-small cell lung carcinoma: This finding has been validated in the phase III ACHILLES study, which reported superior PFS with afatinib (10.6 months) over platinum plus pemetrexed (5.7 months) in NSCLC patients with uncommon EGFR mutations [7].